Attachment_J.4_IEE_Amendment___02_(DCN_Asia_19-009).pdf

ENVIRONMENTAL COMPLIANCE FACESHEET & AMENDMENT #2

TO THE INITIAL ENVIRONMENTAL EXAMINATION (IEE)

Objective: Objective 3/ Investing in People Program Areas: 3.1 Health

Program Elements: 3.1.1 HIV, 3.1.2 Tuberculosis, 3.1.5 Other Public Health Threats, 3.1.6 Maternal and Child Health, 3.1.7 Family Planning and Reproductive Health

Country/Region: Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan

Life of Project (LOP) Amount $219 million (ceiling for LOP: 2012-2025)

Funding Period covered: FY2019 – FY2025 (estimated) Resource Levels/Amount(s): Estimated $100 million1

Statement Prepared by: Arman Toktabayanov, Health and Education Office, USAID/CA Date: November 30, 2018

IEE Amendment? Yes☒ References: Original Programmatic Health IEE (P-IEE): Asia 12-213 (FY2012-

FY2016) 2,

P-IEE Amendment #1, Asia 14-101 (FY2012-FY2020)3

MTF 1to Asia 14-101 (Stop TB) (FY2020-FY2022)4

Additional references: USAID Worldwide Promoting the Quality of Medicines

(PQM) IEE GH 14-06 (FY2014-FY2019)5

USAID Global PEPFAR IEE GH 15-20 (2015-2016)6

ENVIRONMENTAL ACTION RECOMMENDED (Place X where applicable)

Categorical Exclusion (CE): Deferral (D):

Positive Determination (PD): Negative Determination (ND):

Negative Determination With Conditions (NDC):

Exemption (E):

1 within Health P-IEE Amendment #1 ceiling 2 https://ecd.usaid.gov/repository/pdf/38779.pdf 3 https://ecd.usaid.gov/repository/pdf/40856.pdf 4 https://ecd.usaid.gov/repository/pdf/51084.pdf 5 https://ecd.usaid.gov/repository/pdf/41151.pdf 6 https://ecd.usaid.gov/repository/pdf/45111.pdf

Asia 19-009

CLIMATE RISK RATING(S): (Place X where applicable) Low: [X] Medium: [X ] High: [- ] Adaptation /Mitigation Measures: Applicable

SUMMARY OF FINDINGS

1.0 THE PURPOSE:

The purpose of this Amendment #2 to the Programmatic Health IEE (Asia 12-213, LOP 2012-2010) is to:

● Reflect on the extension of the LOP end date from 2021 to 2025;

● Timely and duly account for :

o New “Expanding Tuberculosis Identification, Treatment, and Prevention in Central Asia” (TB- CA) Activity with a total planned investment of $34 million over five years (2019 - 2024);

o New Bilateral WHO-PIO TB grant for $4.1 million over three years (2019 - 2021);

o New Mission buy-in for the follow-on to the “Promoting Quality of Medicines” (PQM) field support mechanism for $6.3 million over five years;

o Extended Mission buy-in for the Stop TB Partnership or similar field support mechanism with increased budget of $2.07 million (2019 - 2022); and o Follow-on HIV program activities for HIV Flagship , HIV REACT and HIV Leader, with the budget of about 40 million over five years (2021 – 2025).

o For any future Health activities in Central Asia (CA) and Kyrgyz Republic(KR) for a period of up to seven years

● Confirm that the scope, nature and type of proposed activities is consistent with those of regional and country-specific activities described in the Programmatic Health IEE and its Amendment #1, and stipulate that all previously approved Threshold Decisions and related conditions shall fully apply to new activities;

● Establish that about 95% of Program funds will be used for activities under approved Categorical Exclusion (CE) and only 5% of program funds will be used for activities under approved Negative Determination with Conditions (NDC);

● Establish that for buy-ins to central awards additional guidance and conditions should be distilled from and refined as warranted from Stop TB Partnership MTF 1 to Asia 14-101 and USAID Worldwide Global Health Bureau PQM IEE (GH 14-06) and/ or other applicable IEEs; for HIV activities, distilled and refined from USAID Global PEPFAR Programmatic IEE GH 15-20.

● Conduct first review of climate risk screening and management for proposed Health activities as required by the ADS 201mal ( see section 3.2 below and Annex 1) and stipulate that prior to commencement of activities under approved NDC, the implementing partner (IP) shall conduct climate risk screening (CRS) for all sectoral and sub-sectoral activities (see:

https://www.usaid.gov/ads/policy/200/201mal);

● Stipulate that projects/activities' CRS for activities under NDC shall be presented in Environmental Review Checklist (ERC), and appropriate commensurate mitigation and adaptation measures shall be developed and presented in integrated Environmental Mitigation and Monitoring plans (EMMP), as part of ERC. ERC template is enclosed (Annex 2). ERCs shall be reviewed and approved by the Central Asia and Kyrgyz Republic Mission Environmental Officer (MEO), Climate Integration Lead (CIL) and Agreement/Contracting Officer Representative (A/COR);

● Establish that for the WHO PIO grant, if the recipient works on components that are not categorically excluded from environmental analysis under 22 CFR 216, USAID will rely upon the WHO’s application of its own environmental policy stipulating for environmental risk review and management of these activities. The recipient will have to provide evidence of adequate environmental and social safeguards in designing, implementing, and monitoring of the activity. This is based on the requirement of the ADS Chapter 308.3.11.c. for cost-type grants to PIO stating that “any environmental conditions proposed to ensure adequate environmental review of the activity proposed should have due regard to both the independence and sovereignty of the PIO and the purpose and intent of the environmental impact assessment requirements of USAID”. If WHO chooses to employ USAID’s environmental compliance procedures, the AOR, MEO and CIL will work with the PIO to ensure consistent with 22CFR216, that a comprehensive environmental impact assessment is undertaken of potential environmental impacts and risks of its activities, the impacts and risks are documented and corresponding mitigation measures are identified, implemented and monitored. WHO is encouraged to evaluate climate related risks and vulnerabilities to adjust activities based on relevant analysis.

● Stipulate that all approved in referenced IEEs Threshold Decisions and conditions shall be fully transposed into procurement instruments;

● Establish that at the post-award conference, the A/COR together with the MEO and CIL shall explain to the implementing partner the approved Threshold Decisions and conditions in force as provided in the IEE Amendment #2; and

● Stipulate that the approved limitations of the IEE and stipulation for revisions remain in force.

2.0 BACKGROUND AND NEW ACTIVITY DESCRIPTION

2.1 Expanding Tuberculosis Identification, Treatment, and Prevention in Central Asia (TB-CA) Activity ( Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan)

Te proposed activity is closely aligned with USAID/Central Asia’s Regional Development Cooperation Strategy (RDCS) and, in particular, with its Development Objective 3: “More effective and inclusive governance institutions that serve the public good.” The Activity will contribute to one Intermediate Result (IR) and three sub-IRs:

o IR 3.3: Increased use of health, education and other services by target population.

o Sub-IR 3.3.1: Increased access to services o Sub-IR 3.3.2: Improved quality of services o Sub-IR 3.3.3: Evidence-based laws, policies, and processes implemented

The purpose of the new TB Flagship Project (henceforth called TB Flagship) is to reduce the burden of TB in Central Asia by building local and regional capacity for improving the detection and treatment of drug-resistant tuberculosis (DR-TB). USAID will support services that will lead to measurable and sustainable improvements in the ability of the health systems in Central Asia to deliver quality DR-TB services by building the leadership, management, financing, and technical capacity of Central Asian institutions, communities, and civil society.

The end result will be increased access to quality DR-TB diagnosis and appropriate treatment, improved TB and DR-TB treatment success, and an enhanced enabling environment promoting financially sustainable DR-TB services that meet international standards. Interventions will target both facility- and community-level DR-TB services. The overarching objective is to improve the detection and treatment of DR-TB to reduce the overall burden of TB in Central Asia. This includes a strong focus on:

● Improving access to and quality of DR-TB services;

● Strengthening leadership and governance of DR-TB services within the health system, including improved financing;

● Strengthening data collection systems and capacity to analyze these data for decision-making;

● Improving coordination of DR-TB services within the broader health sector; and

● Engaging civil society and subnational government to improve support for people with DR-TB and to reduce stigma and discrimination.

The Activity will support national and local government institutions to reduce the burden of TB in Central Asia by building local and regional capacity for improving the detection and treatment of drug-resistant tuberculosis (DR-TB) and it will include the following objectives:

Objective 1: Increased detection of TB and DR-TB Since TB is an airborne infectious disease, to reduce DR-TB transmission it is essential to identify people with active DR-TB early and start them on appropriate treatment as soon as possible. A number of factors contribute to detection delays among people with DR-TB in Central Asia: inadequate information about TB symptoms and services; limited access to appropriate diagnostic tests; delays in conducting and transmitting results of diagnostic tests; delays in TB contact tracing; and stigma and discrimination. Limited integration of TB services within primary health care services is a significant factor in delaying identification of TB symptoms and connecting symptomatic people with appropriate diagnostic testing.

Expected Illustrative Activities:

Strengthen community knowledge and awareness of TB and drug-resistant TB (DR-TB) through civil society organizations (CSOs) and non-governmental organizations (NGOs) in order to increase TB and DR-TB case detection and reduce stigma and discrimination against TB patients, especially from vulnerable populations;

Support outreach and follow-up of those on TB and DR-TB treatment through local CSOs and NGOs for improved continuum of treatment and care and to address the special psycho-social needs of populations vulnerable to TB and DR-TB, including prisoners, migrants, and other socially disadvantaged groups;

Support Ministry of Health (MOH) to promote rational use and maintenance of GeneXpert technology for improved DR-TB outcomes;

Support updating/or development and dissemination of national guidelines, clinical and treatment protocols for scaled up rollout of rapid TB diagnostic technologies such as GeneXpert, line probe assays (LPA) and other laboratory DR-TB rapid diagnostics recommended by WHO;

Provide trainings for laboratory specialists on laboratory logistics management, forecasting of laboratory supplies and consumables, including planning for routine equipment servicing needs;

Provide trainings and certification of national laboratory engineers for repair and timely calibration of laboratory equipment;

Assist in development of sustainable sputum transport systems to ensure faster, more reliable sputum transportation to laboratories;

Objective 2: Increased treatment success for TB and all types of DR-TB To reduce disease transmission, people with DR-TB should be started on appropriate treatment as soon as possible. Non-adherence to treatment can lead to even greater drug resistance, failure of treatment, and continued transmission of TB. Access to TB services can be limited, in particular, due to geography. Additional challenges include limited availability of drugs to treat various forms of DR-TB (including limited access to and barriers to use of new TB drugs), limited capacity to treat DR-TB, policies/guidelines not updated in line with current DR-TB treatment recommendations, and the like. Taking into account the recent updates to WHO treatment guidelines on DR-TB there is a need to provide technical assistance to Central Asian countries to ensure they are able to implement the newest WHO recommendations for DR-TB detection and treatment, infection control, and latent TB infection where appropriate.

Expected Illustrative Activities:

Strengthen National TB Program (NTP) and regional DR-TB treatment facilities capacity to improve detection of DR-TB cases (all forms) and to ensure their timely enrollment on appropriate treatment, including new drugs and shorter treatment regimens;

Improve access to new drugs and shorter treatment regimens all DR-TB cases diagnosed;

Improve quality of DR-TB case management (including management of co-morbidities) to improve adherence to treatment;

Implement countrywide an active TB drug-safety monitoring system (aDSM);

Expanded outpatient treatment and case management of DR-TB in line with WHO best practice standards;

Strengthen capacity of National TB Program (NTP) on TB drug management, including new drugs;

Continue support countrywide implementation of innovative models for outpatient TB and DR-TB treatment with provision of comprehensive case management services to encourage treatment adherence and successful completion of treatment;

Develop and implement patient support adherence strategies, including psycho-social support interventions, use of incentives and enablers;

Develop and strengthen approaches to patient education to improve treatment outcomes;

Engage primary health care (PHC) providers and treatment supporters to improve quality of TB and DR-

TB treatment at community level as well as within the PHC system;

Support human resource (HR) capacity building through training and mentoring within the NTP on TB and

DR-TB management, including new drugs and shorter treatment regimens;

Objective 3: Improved enabling environment and financial sustainability of TB and DR-TB programs To move toward ending TB, it is necessary to work within the health system, but beyond it as well. This objective includes areas that cut across both DR-TB detection and treatment, addressing critical factors that hamper National TB Programs from reaching their goals. Improving the underlying enabling environment would serve as a critical part in achieving the anticipated results.

Expected Illustrative Activities:

Support NTP to facilitate a countrywide transition to outpatient treatment and case management for TB and

DR-TB according to WHO recommendations;

Advocate and promote a dialogue with the government officials to increase national TB funding;

Support development of new approaches for financing TB programs per case and promote development of a plan for investing savings from TB bed optimization into outpatient treatment with a patient-centered approach and TB/DR-TB drug procurement.

Strengthen collaboration between TB services and PHC to improve the referrals of TB and DR-TB suspects for appropriate and timely diagnosis and treatment;

Support the roll-out of TB/DR-TB electronic information management system countrywide r for collection, analyzing, reporting and decision making at all levels;

Improve NTP staff capacity at central and oblast levels on data analysis, use of data for decision making;

Document and disseminate best practices and implementation models within the region.

2.2. WHO PIO activity (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan)The proposed activity is closely aligned with USAID/Central Asia’s Regional Development Cooperation Strategy (RDCS) and, in particular, with its Development Objective 3: “More effective and inclusive governance institutions that serve the public good.” The Activity will contribute to one Intermediate Result (IR) and three sub-IRs:

o IR 3.3: Increased use of health, education and other services by target population.

o Sub-IR 3.3.1: Increased access to services o Sub-IR 3.3.2: Improved quality of services o Sub-IR 3.3.3: Evidence-based laws, policies, and processes implemented

The proposed activity builds on the unique position of WHO as a “neutral party” that can deliver assistance at national level. WHO has established productive relationships in TB area and will complement other TB activities. Due to the high DR TB prevalence, the main focus will be on combating DR TB. Through WHO USAID will support the overall goals of National Tuberculosis (TB) Programs (NTP) across Central Asia to reduce the burden of TB and DR-TB and assist local governments to provide universal and equitable access to high quality TB services including vulnerable populations. The WHO will provide technical assistance mostly at national level to support the introduction and scale-up of the latest WHO-recommended guidelines for TB and drug-resistant DR-TB. It will support the Ministry of Health’s (MoH) national program by improving their capacity to plan, implement, monitor and evaluate TB and DR-TB action plans, and improve coordination with donors and national stakeholders. The WHO will be engaged at national level to work with health policy-makers, NTPs, and health care staff to adapt international recommendations to shift treatment services from in-patient hospital care to outpatient treatment that involves civil society organizations, communities and family members. Special attention will be paid to improving the quality of and access to second-line TB drug treatment for DR-TB patients, as well as to childhood TB treatment through implementation of updated guidelines based on the latest WHO recommendations. This activity will primarily work in Uzbekistan and Turkmenistan, but have limited regional activities as well. It’s important to highlight that WHO engagement is especially critical in Turkmenistan, where NGO licensing is very difficult to obtain.

Expected Illustrative Activities:

Strengthening technical and managerial capacity of NTP and MoH through trainings and technical assistance provided by WHO experts;

Strengthening effective coordination between country stakeholders and NTP/MOH as well as other relevant government ministries and agencies on development/ or updating the relevant orders, guidelines and protocols based on WHO recommendations as well as to assist on updating the national health finance policies related to TB and inclusion of TB in the health reform process;

Support and facilitate participation of key national partners in international training courses and presentation in international conferences (3-5 persons each year);

Improve programmatic management of DR-TB, childhood TB and TB/HIV through updating all relevant national clinical protocols and guidelines, as well as to improve national capacity for scaling-up implementation of new drugs and shorter treatment regimens by knowledge transfer and on-job training delivered by an international experts;

Provide a regional workshop to share the best practices on outpatient (ambulatory) treatment and care for TB and DR-TB;

Improve the TB/DR-TB epidemiological surveillance and comprehensive monitoring and evaluation system through technical assistance missions, development of training and supervision activities plans, as well as providing trainings at national and oblast level to help analyze the data, and to use these data for decision making to improve the TB program performance.

Promote partnership and advocacy activities through the development of a comprehensive advocacy and communication campaign, organizing quarterly interagency coordinating meetings to exchange visions, plans and status of national and international assistance to TB control in the country.

2.3. Promoting Quality of Medicines Follow-on Activity in Kazakhstan and Uzbekistan The proposed activity is closely aligned with USAID/Central Asia’s Regional Development Cooperation Strategy (RDCS) and, in particular, with its Development Objective 3: “More effective and inclusive governance institutions that serve the public good.” The Activity will contribute to one Intermediate Result (IR) and three sub-IRs:

o IR 3.3: Increased use of health, education and other services by target population.

o Sub-IR 3.3.1: Increased access to services o Sub-IR 3.3.2: Improved quality of services o Sub-IR 3.3.3: Evidence-based laws, policies, and processes implemented

Focused primarily on Kazakhstan and Uzbekistan, this activity will provide technical assistance to improve the quality of anti-TB medicines produced by the major medicines manufacturers in the country and enhancing the capacity of these manufacturers to comply with international Good Manufacturing Practices (GMPs). Because of use of inappropriate or low-quality TB drugs creates further TB drug resistance, and adds to the growing TB control crisis. Still the quality of medicines remains a problem in the region. The Promoting Quality of Medicines (PQM) project will provide technical assistance to tuberculosis (TB) pharmaceutical manufacturers to build their capacity to produce high quality anti-TB medicines to ensure compliance with international standards of Good Manufacturing Practices (GMP). The project also helps improve the quality and standards of pharmaceutical testing laboratories so that they can receive International Organization of Standardization (ISO) accreditation and are thus able to accurately assure the quality of TB drugs being used in the countries.

Working directly with pharmaceutical companies to develop GMPs is highly specialized and this Field Support mechanism is uniquely suited for this activity. It is highly unlikely that any other organization will have this skill set. As access to low cost/high quality locally manufactured drugs is a key aspect of long-term sustainability, this activity will support the Journey to Self-Reliance, both in Kazakhstan, and Uzbekistan.

2.4. Stop TB Partnership Activity in Kazakhstan and Tajikistan ( described and screened in the MTF 1 to Asia 14-101)

2.5 Follow-on HIV Activities

USAID is funding the Central Asia HIV Flagship Activity, the HIV React Activity, and the Leader for PLHIV Activity until December 2020. After 2020, USAID will continue follow-on activities described in the original P-IEE including the following:

● Advocacy and support to governments to increase investment in HIV and its effectiveness;

● Advocacy and policy changes for reducing stigma and discrimination against key populations and people living with HIV:

● Advocacy and capacity building of local NGOs participation in the national epidemic control;

● Advocacy and capacity building for implementing innovative services at the community level (rapid testing and treatment services)

● Capacity building of local NGOs in providing services to KP and PLHIV (case finding and case management)

● Sub-contracting to local NGOs to provide services to KP and PLHIV (case finding and case management)

● Procurement of kits for rapid HIV testing and self-testing at the community level. Procurement of commodities for HIV prevention such as condoms and lubricants.

2.6 Lessons Learned

During 2014-2018, all USAID/Health activities were in full compliance with USAID requirements established in P-IEEs. A/ CORs and MEO visited multiple project sites and conducted environmental compliance monitoring of these activities. Practically all activities qualified for a Categorical Exclusion and didn’t require environmental screening, mitigation, monitoring and reporting to USAID. In several cases limited amount of office electric and electronic and medical equipment was procured and related small renovation activities took place. This was reported in accordance with P-IEE conditions.

3.0 ENVIRONMENTAL COMPLIANCE SCREENING OF NEW ACTIVITIES

3.1 Environmental compliance screening

It is expected that about 95 % of funding for new and follow-on activities fall under Categorical Exclusion and will not require further environmental review and reporting to USAID. However, many activities listed in all referenced above IEEs, IEE amendments and MTF may directly or indirectly affect the environment or have the potential to do so through small construction/renovation activities; procurement of electric and electronic equipment; exposure to infectious material and the generation and disposal of hazardous or highly hazardous medical waste. If the implementing partner works on such NDC activities it will have to provide environmental management in accordance with terms established in this Amendment.

3.2 Climate risk screening

USAID has completed climate risk profile and fact sheet for Central Asia region as well as country-specific profiles for Kazakhstan, Kyrgyz Republic, and Uzbekistan . They were posted on http://www.climatelinks.org and are available at: https://www.climatelinks.org/sites/default/files/asset/document/2018-April- 30_USAID_CadmusCISF_Climate-Risk-Profile-Central-Asia.pdf. GHG Emissions factsheets for Kazakhstan and Kyrgyz Republic are also available on http://www.climatelinks.org. Based on results of EC screening available in these profiles and fact sheets, all new activities components are rated as Low or Moderate Climate Risk (see Annex 1 for Climate Risk Management summary table). Additional climate risk screening should be conducted for NDC activities by the IP (s) as required by ADS 201mal. The IP may use sources referenced in the Climate Change Risk Profiles at https://www.climatelinks.org.

3.3 Recommended Actions:

a) Categorical Exclusion (more 95% of funding) - pursuant to 22 CFR 216.2(c)(2)(i), the originator of the activities has determined that Activities consist of types of interventions entirely within the categories listed in paragraph (c)(2), "Categorical Exclusions," of Section 216.2, "Applicability of Procedures," of Title 22 CFR Part 216, "AID Environmental Procedures", and therefore are categorically excluded from any further environmental review requirements. The originator of the proposed action has further determined that the proposed activities are fully within the following classes of actions:

-Education, technical assistance, or training programs except to the extent such programs include activities directly affecting the environment (such as construction of facilities, etc.) [22 CFR 216.2(c)(2)(i)];

-Analyses, studies, academic or research workshops and meetings [22 CFR216.2(c)(2)(iii)];

-Document and information transfers [22 CFR 216.2(c)(2)(v)];

-Studies, projects or programs intended to develop the capability of recipient countries to engage in development planning, except to the extent designed to result in activities directly affecting the environment (such as construction of facilities, etc. [22 CFR 216.2(c)(2)(xiv)]

b) Negative Determination with Conditions (less than 5% of funding) is recommended for activities involving actions that directly or indirectly affect the physical or natural environments specified in Table 2, Sections II and III of original Health P-IEE.

4.0 REVISIONS

Pursuant to 22 CFR 216.3(a)(9), if new information becomes available which indicates that activities to be funded by the Project might be "major" and the Program's effect "significant", approved threshold determinations will be reviewed and revised by the originator of the project and submitted to the Asia Bureau Environmental Officer (BEO/Asia)for approval and, if appropriate, an environmental assessment will be prepared. It is the responsibility of the USAID A/COR to timely inform the USAID/CA and USAID KR MEO/CILs, and the BEO/Asia of any changes in scope and nature of the approved activities that might require revision of the approved Threshold decisions.

USAID/CA and KR Missions shall regularly check the implementers on implementation of activities, and shall assure that all activities are in full compliance with the environmental conditions approved in the original and amended IEEs.

12/4/2018

X

Climate Risk Management Table

Annex 1

Defined or Anticipated Project Elements

Climate Risks Risk Ratin g

How Risks are Addressed at Project Level ‐

Further Analysis and Actions for Activity Design/ Implementati on

Opportunities to Strengthen Climate Resilience

All TB and HIV Health activities:

LOP: FY 19‐

FY 2025

(Multiple awards)

NDC

elements:

1.Trainings and workshops 2.Small construction /rehabilitati on of facilities

3.Provision of laboratory and office equipment, medical kits, chemical reagents, personal protective equipment

4. Infectious

Climate change poses a higher threat of air temperature rise in Central Asia above global mean increases, causing droughts in low land plains, heat waves, heavy rainfalls and increased frequency of extreme events (mudflows, avalanches, etc) in most parts of Central Asia.

There might be different (direct and indirect) ways of climate change impact on TB development and planned activities‐ 1.‐Participants may not be able to get to training venues due to flooding or other extreme weather events especially in mountain areas;

2‐3.Installed equipment might be damaged along with health infrastructure.

4.Cold chain might be

1.L

2 ‐ 3.

M

At Project level no climate risks were addressed as PADs were developed before the issue of ADS 201mal.

However, climate change adverse consequences have been taken into account at an activity design stage as IEE included a requirement to consider all possible environmental conditions to ensure sound environmental design, including climate change.

This was included in requirements for sub‐awards, pilots, demonstrations related to small construction/ renovation, equipment supply and in trainings.

IP will have to conduct additional climate risk analysis for NDC activities.

This condition shall be included in the award environmental compliance language.

Any visible impact of climate change on project implementation will be documented to inform future programming and development of adaptation measures.

These mechanisms may work jointly with the government to:

‐Include climate resilience in Health sector in future policies, strategies and programming.

‐ Increase the capacity of health care and emergency services to support disaster planning and management to ensure continued services during a disaster;

‐ Recommend inclusion of climate resilience in policies and procedures that may include relocation of some clinics.

‐ Consider increased distribution of bed nets for mosquito‐borne diseases.

‐ Find alternative routes to project sites and event venues;

‐ Consider virtual site visits and trainings ‐ Consider flexibility built in schedule/virtual meeting ‐ Consider energy efficient technologies for cold chain transport disease diagnosis

5.Monitorin g and evaluation impacted by flooding and /or extreme heat ‐Proper waste management may be compromised

5. Access to project sites may be delayed due to extreme events

4.M

5.L

Annex 2

ENVIRONMENTAL REVIEW CHECKLIST

FOR IDENTIFYING POTENTIAL

ENVIRONMENTAL IMPACTS

OF PROJECT ACTIVITIES AND

PROCESSES

for [Activity Name]

Implemented under: [Project Name]

DCN: [of Parent IEE]

Prepared by: [Implementer]

ENVIRONMENTAL REVIEW CHECKLIST FOR IDENTIFYING POTENTIAL

ENVIRONMENTAL IMPACTS OF PROJECT ACTIVITIES AND PROCESSES

The Environmental Review Checklist for Identifying Potential Environmental Impacts of Project Activities and Processes (ERC) is intended for use mainly by implementing partners to: assess activity-specific baseline conditions, including applicable environmental requirements; identify potential adverse environmental effects associated with planned activity(s) and processes; and develop environmental mitigation and monitoring plans (EMMPs) that can effectively avoid or adequately minimize the identified effects. This ERC can also be substituted for other ERC versions that may have been attached to project initial environmental examinations (IEE). If implementing partners are in doubt about whether a planned activity requires preparation of an ERC, they should contact their Contracting Officer’s Representative (COR)/Agreement Officer’s Representative (AOR) for clarification. (When preparing the checklist, please indicate “not applicable” for items that have no bearing on the activity.)

A. Activity and Site Information Project Name: (as stated in the triggering IEE)

Mission/Country:

DCN of Triggering IEE:

Activity/Site Name:

Type of Activity:

Name of Reviewer and Summary of Professional Qualifications:

Date of Review:

B. Activity Description

1. Activity purpose and need

2. Location of activity

3. Beneficiaries, e.g., size of community, number of school children, etc.

4. Number of employees and annual revenue, if this is a business

5. Implementation timeframe and schedule

6. Detailed description of activity and site, e.g., size of the facility or hectares of land; steps that will be taken to accomplish the activity

7. Existing or planned certifications, e.g., ISO 14001 EMS, ISO 9000, HCCP, SA 8000, Global

Gap, Environmental Product Declarations, Eco Flower, EcoLogo, Cradle to Cradle, UL Environment, GREENGUARD, Fair Trade, Green Seal, LEED, or various Forest Certifications

8. Site map, e.g., provide an image from Google Earth of the location

9. Photos of site (when available)

C. Activity-Specific Baseline Environmental Conditions

1. Population characteristics

2. Geography

3. Natural resources, e.g., nearby forest/protected areas, ground and surface water resources

4. Current land use

5. Proximity to public facilities, e.g. schools, hospitals, etc.

6. Other relevant description of current environmental conditions in proximity to the activity

D. Legal, Regulatory, and Permitting Requirements

1. National environmental impact assessment requirements for this activity

2. Applicable National or local permits for this activity, responsible party, and schedule for obtaining them:

Permit Type Responsible party Schedule Zoning Building/Construction Source Material Extraction Waste Disposal Wastewater Storm Water Management Air Quality Water Use Historical or Cultural Preservation Wetlands or Water bodies Threatened or Endangered Species Other

3. Additional national or other international environmental laws, conventions, standards with which the activity might be required to comply

a. Air emission standards

b. Water discharge standards

c. Solid waste disposal or storage regulations

d. Hazardous waste storage and disposal

e. Historical or cultural preservation

f. Other

E. Engineering Safety and Integrity (for Sections E. and F., provide a discussion for any of the listed issues that are likely to have bearing on this activity)

1. Will the activity be required to adhere to formal engineering designs/plans? Have these been or will they be developed by a qualified engineer?

2. Do designs/plans effectively and comprehensively address:

a. Management of storm water runoff and its effects?

b. Reuse, recycling, and disposal of construction debris and by-products?

c. Energy efficiency and/or preference for renewable energy sources?

d. Pollution prevention and cleaner production measures?

e. Maximum reliance on green building or green land-use approaches?

f. Emergency response planning?

g. Mitigation or avoidance of occupational safety and health hazards?

h. Environmental management of mobilization and de-mobilization?

i. Capacity of the host country recipient organization to sustain the environmental management aspects of the activity after closure and handover?

3. Are there known geological hazards, e.g., faults, landslides, or unstable soil structure, which could affect the activity? If so, how will the project ensure structural integrity?

4. Will the site require grading, trenching, or excavation? Will the activity generate borrow pits? If so, how will these be managed during implementation and closure?

5. Will the activity cause interference with the current drainage systems or conditions?

Will it increase the risk of flooding?

6. Will the activity interfere with above- or below-ground utility transmission lines, e.g., communications, water, sewer, or natural gas?

7. Will the activity potentially interfere with vehicle or pedestrian traffic?

8. Does the activity increase the risk of fire, explosion, or hazardous chemical releases?

9. Does the activity require disposal or retrofitting of polychlorinated biphenyl-containing equipment, e.g., transformers or florescent light ballasts?

F. Environment, Health, and Safety Consequences

1. Potential impacts to public health and well-being

a. Will the activity require temporary or permanent property land taking?

b. Will activities require temporary or permanent human resettlement?

c. Will area residents and/or workers be exposed to pesticides, fertilizer, or other toxic substances, e.g., as a result of farming or manufacturing? If so, how will the project:

i. Ensure that these chemicals do not contaminate ground or surface water?

ii. Ensure that workers use protective clothing and equipment to prevent exposure?

iii. Control releases of these substances to air, water, and land?

iv. Restrict access to the site to reduce the potential for human exposure?

d. Will the activity generate pesticide, chemical, or industrial wastes? Could these wastes potentially contaminate soil, groundwater or surface water?

e. Will chemical containers be stored at the site?

f. Does the activity remove asbestos-containing materials or use of building materials that may contain asbestos, formaldehyde, or other toxic materials? Can the project certify that building materials are non-toxic? If so, how will these wastes be disposed of?

g. Will the activity generate other solid or hazardous wastes such as construction debris, dry or wet cell batteries, florescent tubes, aerosol cans, paint, solvents, etc.? If so, how will this waste be disposed of?

h. Will the activity generate nontoxic, nonhazardous solid wastes (subsequently requiring land resources for disposal)?

i. Will the activity pose the need to handle and dispose of medical wastes? If so, describe measures of ensuring occupational and public health and safety, both onsite and offsite.

j. Does the activity provide a new source of drinking water for a community? If so, how will the project monitor water quality in accordance with health standards?

k. Will the activity potentially disturb soil contaminated with toxic or hazardous materials?

l. Will activities, e.g., construction, refurbishment, demolition, or blasting, result in increased noise or light pollution, which could adversely affect the natural or human environment?

2. Atmospheric and air quality impacts

a. Will the activity result in increased emission of air pollutants from a vent or as fugitive releases, e.g., soot, sulfur dioxide, oxides of nitrogen, volatile organic compounds, methane.

b. Will the activity involve burning of wood or biomass?

c. Will the activity install, operate, maintain, or decommission systems containing ozone depleting substances, e.g., freon or other refrigerants?

d. Will the activity generate an increase in carbon emissions?

e. Will the activity increase odor and/or noise?

3. Water quality changes and impacts

a. How far is the site located from the nearest river, stream, or lake?

b. Will the activity disturb wetland, lacustrine, or riparian areas?

c. What is the depth to groundwater at the site?

d. Will the activity result in increased ground or surface water extraction? If so, what are the volumes? Permit requirements?

e. Will the activity discharge domestic or industrial sewage to surface, ground water, or publicly-owned treatment facility?

f. Does the activity result in increased volumes of storm water run-off and/or is there potential for discharges of potentially contaminated (including suspended solids) storm water?

g. Will the activity result in the runoff of pesticides, fertilizers, or toxic chemicals into surface water or groundwater?

h. Will the activity result in discharge of livestock wastes such as manure or blood into surface water?

i. Does the site require excavation, placing of fill, or substrate removal (e.g., gravel) from a river, stream or lake?

4. Land use changes and impacts

a. Will the activity convert fallow land to agricultural land?

b. Will the activity convert forest land to agricultural land?

c. Will the activity convert agricultural land to commercial, industrial, or residential uses?

d. Will the activity require onsite storage of liquid fuels or hazardous materials in bulk quantities?

e. Will the activity result in natural resource extraction, e.g., granite, limestone, coal, lignite, oil, or gas?

f. Will the activity alter the viewshed of area residents or others?

5. Impacts to forestry, biodiversity, protected areas and endangered species

a. Is the site located adjacent to a protected area, national park, nature preserve, or wildlife refuge?

b. Is the site located in or near threatened or endangered (T&E) species habitat? Is there a plan for identifying T&E species during activity implementation? If T&E species are identified during implementation, is there a formal process for halting work, avoiding impacts, and notifying authorities?

c. Is the site located in a migratory bird flight or other animal migratory pathway?

d. Will the activity involve harvesting of non-timber forest products, e.g., mushrooms, medicinal and aromatic plants (MAPs), herbs, or woody debris?

e. Will the activity involve tree removal or logging? If so, please describe.

6. Historic or cultural resources

a. Are there cultural or historic sites located at or near the site? If so, what is the distance from these? What is the plan for avoiding disturbance or notifying authorities?

b. Are there unique ethnic or traditional cultures or values present in the site? If so, what is the applicable preservation plan?

G. Further Analysis of Recommended Actions (if the applicable IEE requires the use of ERCs to perform further analysis of recommended actions, then check the appropriate box below. If this analysis is not required, then skip this and proceed with Section H. If required by the IEE, the ERC shall be copied to the Bureau Environmental Officer (BEO)).

☐ 1. Categorical Exclusion: The activity is not likely to have an effect on the natural or physical environment. No further environmental review is required.* ☐ 2. Negative Determination with Conditions: The activity does not have potentially significant adverse environmental, health, or safety effects, but may contribute to minor impacts that can be eliminated or adequately minimized by appropriate mitigation measures. EMMPs shall be developed, approved by the Mission Environmental Officer (MEO) (and the BEO if required by the IEE) prior to beginning the activity, incorporated into workplans, and then implemented. See Sections H and I below.* ☐ 3. Positive Determination: The activity has potentially significant adverse environmental effects and requires further analysis of alternatives, solicitation of stakeholder input, and incorporation of environmental considerations into activity design. A Scoping Statement must be prepared and be submitted to the BEO for approval. Following BEO approval an Environmental Assessment (EA) will be conducted. The activity may not be implemented until the BEO clears the final EA. For activities related to the procurement, use, or training related to pesticides, a PERUSAP will be prepared for BEO approval.

☐ 4. Activity Cancellation: The activity poses significant and unmitigable adverse environmental effects. Adequate EMMPs cannot be developed to eliminate these effects and alternatives are not feasible. The project is not recommended for funding.

*Note regarding applicability related to Pesticides (216.2(e): The exemptions of §216.2(b)(l) and the categorical exclusions of §216.2(c)(2) such as technical assistance, education, and training are not applicable to assistance for the procurement or use of pesticides.

H. EMMPs (Using the format provided below, or its equivalent, list the processes that comprise the activity, then for each, identify impacts requiring further consideration, and for each impact describe the mitigation and monitoring measures that will be implemented to avoid or adequately minimize the impacts. All environment, health, and safety impacts requiring further consideration, which were identified in Section F., should be addressed)

1. Activity-specific environmental mitigation plan (Upon request, the MEO may be able to provide your project with example EMMPs that are specific to your activity.)

Processes Identified Environmental

Impacts

Do the Impacts Require Further Consideration?

Mitigation Measures

Monitoring Indicators

List all the processes that comprise the activity(s)(e.g.

asbestos roof removal, installation of toilets, remove and replace flooring) A line should be included

A single process may have several potential impacts— provide a separate line for each.

For each impact, indícate Yes or No; if No, provide justification, e.g.,:

(1) There are no applicable legal requirements including permits or reporting and

(2) There is no relevant community concern and

(3) Pollution prevention is not

For each impact requiring further consideration, describe the mitigation measures that will avoid or adequately minimize the impact. (If mitigation measures are well-specified in the IEE, quote directly from IEE.)

Specify indicators to (1) determine if mitigation is in place and (2) successful.

For example, visual inspections for seepage around pit latrine;

sedimentation at for each process.

feasible or practical and

(4) Does not pose a risk because of low severity, frequency, or duration stream crossings, etc.)

2. Activity-specific monitoring plan Monitoring Indicators Monitoring and Reporting

Frequency Responsible

Parties Records

Generated Specify indicators to (1) determine if mitigation is in place and (2) successful (for example, visual inspections for seepage around pit latrine;

sedimentation at stream crossings, etc.)

For example:

“Monitor weekly, and report in quarterly reports.

If XXX occurs, immediately inform USAID COR/AOR.”

Separate parties responsible for mitigation from those responsible for reporting, whenever appropriate, If appropriate, describe types of records generated by the mitigation, monitoring, and reporting process.

I. Certification of No Adverse or Significant Effects on the Environment I, the undersigned, certify that activity-specific baseline conditions and applicable environmental requirements have been properly assessed; environment, health, and safety impacts requiring further consideration have been comprehensively identified; and that adverse impacts will be effectively avoided or sufficiently minimized by proper implementation of the EMMP(s) in Section G. If new impacts requiring further consideration are identified or new mitigation measures are needed, I will be responsible for notifying the USAID COR/AOR, as soon as practicable. Upon completion of activities, I will submit a Record of Compliance with Activity- Specific EMMPs using the format provided in ERC Annex 1 or its equivalent.

Implementer Project Director/COP Name Date

J. Approvals:

USAID COR/AOR Name

Date

Mission Environmental Officer Name

Date

Distribution:

● Project Files

● Bureau Environmental Officer

ERC ANNEX 1

RECORD OF COMPLIANCE WITH ACTIVITY-SPECIFIC

ENVIRONMENTAL MITIGATION AND MONITORING PLANS (EMMPs)

Subject: Site or Activity Name/Primary Project Name/IEE DCN Number

To: COR/AOR/Activity Manager Name Copy: Mission Environmental Officer Name Date:

The [name of the implementing organization] has finalized its activities at the [site name] to [describe activities and processes that were undertaken]. This memorandum is to certify that our organization has met all conditions of the EMMPs for this activity. A summary of the how mitigation and monitoring requirements were met is provided below.

1. Mobilization and Site Preparation

2. Activity Implementation Phase

3. Site Closure Phase

4. Activity Handover

Sincerely, Implementer Project Director/COP Name

Date

Approved:

USAID/COR/AOR/Activity Manager Name

Date

Distribution:

● Project Files

● MEO

● Bureau Environmental Officer